Glatiramer Acetate Depot Injection Shows T1 and T2 Lesion Reduction in Relapsing MS
February 24th 2023Secondary findings from a phase 3 study demonstrate a significant decrease in new T1 enhancing lesions and new enlarging hyperintense T2 lesions in patients with multiple sclerosis undergoing glatiramer acetate depot treatment.
The Mount Sinai Perspective on the State of MS Care: Stephen Krieger, MD
August 5th 2022The neurologist at the Corinne Goldsmith Dickinson Center for MS offered an overview of the State of the Science Summit that was held on June 30, 2022, with a variety of expert clinicians from Mount Sinai. [WATCH TIME: 7 minutes]
The Future of Care and Focusing on Brain Health in MS to Maximize Reserve
May 30th 2022Stephen Krieger, MD, of the Icahn School of Medicine and Corinne Goldsmith Dickinson Center for MS at Mount Sinai, shared his perspectives on the trends in multiple sclerosis and the need to holistically treat patients to maximize brain reserve.
An AI Morphology Array’s Potential to Improve Parkinson Diagnosis
May 13th 2022John F. Crary, MD, PhD, and Jerry Fernandez, MD, offer insight into PreciseDx's AI Morphology Feature Array and how this technology can improve neuropathology and diagnosis for neurodegenerative diseases, such as Parkinson disease.
Combination Agent P2B001 Shows Promise for Parkinson Disease in Phase 3 Data
April 5th 2022The Pharma Two B therapy combines a dopamine agonist, pramipexole, and an MAO-B inhibitor, rasagiline, and has shown significant improvements on UPDRS total scores and ESS scores for untreated patients with PD.